These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 16129520)

  • 1. [Proteasome inhibitors].
    Alexandre J
    Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of bortezomib in the treatment of multiple myeloma.
    Cavo M
    Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
    Soria JC
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
    [No Abstract]   [Full Text] [Related]  

  • 6. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
    MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib for multiple myeloma.
    Popat R; Joel S; Oakervee H; Cavenagh J
    Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
    Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition in the treatment of cancer.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the proteasome inhibitor bortezomib in multiple myeloma.
    Richardson PG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1321-31. PubMed ID: 15163277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.